Literature DB >> 10933965

Retroviral delivery of peptide modulators of cellular functions.

J B Lorens1, M K Bennett, D M Pearsall, W R Throndset, A B Rossi, R J Armstrong, B P Fox, E H Chan, Y Luo, E Masuda, D A Ferrick, D C Anderson, D G Payan, G P Nolan.   

Abstract

Stable transduction of genetic material, in combination with sensitive methodologies for in vivo study of cell physiology, provides an opportunity to efficiently evaluate the functions of regulatory proteins. To dissect the minimal therapeutic function of such proteins, we have stably expressed protein microdomains as fusions, composed of short peptides, and detected specific subfunctions distinct from holoprotein function, using flow cytometry and other techniques. We demonstrate that retroviral delivery of the 24-amino-acid proliferating cell nuclear antigen-binding motif (p21C), derived from the C-terminus of the cell cycle inhibitor protein, p21, is sufficient to induce cell cycle arrest. Cells expressing this peptide motif reversibly execute both G1- and G2-checkpoint controls that are normally activated subsequent to interference with DNA synthesis. The p21C effect is distinct from results obtained with an intact p21 protein that also binds cyclin-CDK complexes and arrested cells exclusively at the G1/S transition. Thus, microdomains can exert unique biological effects compared to the parental molecules from which they were derived. To further evaluate the peptide delivery strategy, we analyzed the role of various kinases in IgE-mediated stimulation of mast cell exocytosis. Primary bone marrow-derived mast cells were transduced with retroviral constructs encoding short-kinase inhibitor motifs and analyzed by flow cytometry for effects on exocytosis. We found that a specific protein kinase A (PKA) inhibitor peptide suppressed IgE-mediated stimulation of mast cell exocytosis. This anti-exocytotic effect was mimicked by a small molecule inhibitor of PKA (KT5720). Thus, the ability to express protein microdomains can be a powerful means to subtly perturb cellular physiology in manners that reveal new paths for therapeutic intervention. We believe that such approaches might allow for new forms of gene therapy to become available.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10933965     DOI: 10.1006/mthe.2000.0063

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  12 in total

1.  Oligonucleotide-directed site-specific integration of high complexity libraries into ssDNA templates.

Authors:  M B Hale; G P Nolan; R Wolkowicz
Journal:  Nucleic Acids Res       Date:  2004-01-29       Impact factor: 16.971

2.  Wilms' tumorigenesis is altered by misexpression of the transcriptional co-activator, CITED1.

Authors:  Harold N Lovvorn; Scott Boyle; Genbin Shi; Yu Shyr; Marcia L Wills; Alan O Perantoni; Mark de Caestecker
Journal:  J Pediatr Surg       Date:  2007-03       Impact factor: 2.545

3.  Suppression of the allogeneic response by the anti-allergy drug N-(3,4-dimethoxycinnamonyl) anthranilic acid results from T-cell cycle arrest.

Authors:  Sarah S Zaher; David Coe; Jian-Guo Chai; Daniel F P Larkin; Andrew J T George
Journal:  Immunology       Date:  2013-02       Impact factor: 7.397

4.  Irod/Ian5: an inhibitor of gamma-radiation- and okadaic acid-induced apoptosis.

Authors:  Tone Sandal; Linda Aumo; Lars Hedin; Bjørn T Gjertsen; Stein O Døskeland
Journal:  Mol Biol Cell       Date:  2003-04-17       Impact factor: 4.138

5.  p21(Cip1) up-regulated during histone deacetylase inhibitor-induced CD4(+) T-cell anergy selectively associates with mitogen-activated protein kinases.

Authors:  Ayse Selma Dagtas; Kathleen M Gilbert
Journal:  Immunology       Date:  2009-09-11       Impact factor: 7.397

6.  Functional cloning of Src-like adapter protein-2 (SLAP-2), a novel inhibitor of antigen receptor signaling.

Authors:  S J Holland; X C Liao; M K Mendenhall; X Zhou; J Pardo; P Chu; C Spencer; A Fu; N Sheng; P Yu; E Pali; A Nagin; M Shen; S Yu; E Chan; X Wu; C Li; M Woisetschlager; G Aversa; F Kolbinger; M K Bennett; S Molineaux; Y Luo; D G Payan; H S Mancebo; J Wu
Journal:  J Exp Med       Date:  2001-11-05       Impact factor: 14.307

7.  Bi-specific TCR-anti CD3 redirected T-cell targeting of NY-ESO-1- and LAGE-1-positive tumors.

Authors:  Emmet McCormack; Katherine J Adams; Namir J Hassan; Akhil Kotian; Nikolai M Lissin; Malkit Sami; Maja Mujić; Tereza Osdal; Bjørn Tore Gjertsen; Deborah Baker; Alex S Powlesland; Milos Aleksic; Annelise Vuidepot; Olivier Morteau; Deborah H Sutton; Carl H June; Michael Kalos; Rebecca Ashfield; Bent K Jakobsen
Journal:  Cancer Immunol Immunother       Date:  2012-12-22       Impact factor: 6.968

8.  Mural cell associated VEGF is required for organotypic vessel formation.

Authors:  Lasse Evensen; David R Micklem; Anna Blois; Sissel Vik Berge; Niels Aarsaether; Amanda Littlewood-Evans; Jeanette Wood; James B Lorens
Journal:  PLoS One       Date:  2009-06-04       Impact factor: 3.240

9.  Enhanced gene expression from retroviral vectors.

Authors:  Magnus Blø; David R Micklem; James B Lorens
Journal:  BMC Biotechnol       Date:  2008-02-25       Impact factor: 2.563

10.  Systematic identification of regulatory proteins critical for T-cell activation.

Authors:  Peter Chu; Jorge Pardo; Haoran Zhao; Connie C Li; Erlina Pali; Mary M Shen; Kunbin Qu; Simon X Yu; Betty Cb Huang; Peiwen Yu; Esteban S Masuda; Susan M Molineaux; Frank Kolbinger; Gregorio Aversa; Jan de Vries; Donald G Payan; X Charlene Liao
Journal:  J Biol       Date:  2003-09-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.